Assessing Expression of TGF- Β2 and PCDH9 Genes in Breast Cancer Patients

Seyed Hesamoddin Bidoki, Arash Bayatani, Mahsa Sarlak, Milad Rasouli, Paria Mostafaie, Mona Saghafi, Alireza Tavakolpour Negari


Background: Breast cancer is the most commonly occurring cancer in women, comprising almost one third of all malignancies in females. The evolution of breast cancer is a multistep process involving genetic, epigenetic, and environmental factor interactions that result in the dysregulation of key oncogenes and tumor suppressor genes, culminating in activation of cancer-related signaling pathways. It has been broadly recognized that cancer is a disease caused by molecular alterations in either proto-oncogenes or tumor suppressor genes. In order to make an impact on breast cancer, we must understand the molecular abnormalities to target better therapeutics.

Methods: The expression status of PCDH9 and TGF-β2 genes were checked in 35 patients with breast cancer tissues and 35 adjacent normal tissues using the q-PCR method.

Result: This paper reported that there was no significant difference between expression level of tumor samples and adjacent normal samples (P > 0.05). However, this study was designed as a pilot study, and further investigations are required to confirm our findings.


Quantitative Real-Time PCR Method; Breast Cancer; PCDH9; TGF-Β2.

Full Text:



ANARY MA, NOOSHIN S, AHMADI AM AND NEGARI AT. 2018. The Expression Analysis of KLF11, PCDH9 and TGF-Β2 Genes in Patients with Non-Small Cell Lung Cancer.

ASIEDU MK, INGLE JN, BEHRENS MD, RADISKY DC AND KNUTSON KL. 2011. TGFβ/TNFα-mediated epithelial–mesenchymal transition generates breast cancer stem cells with a claudin-low phenotype. Cancer research 71: 4707-4719.

BUCK MB AND KNABBE C. 2006. TGF‐Beta Signaling in Breast Cancer. Annals of the New York Academy of Sciences 1089: 119-126.

CHEN Y, XIANG H, ZHANG Y, WANG J AND YU G. 2015. Loss of PCDH9 is associated with the differentiation of tumor cells and metastasis and predicts poor survival in gastric cancer. Clinical & experimental metastasis 32: 417-428.

DE CAESTECKER M. 2004. The transforming growth factor-β superfamily of receptors. Cytokine & growth factor reviews 15: 1-11.

DRUESNE-PECOLLO N, TOUVIER M, BARRANDON E, CHAN DS, NORAT T, ZELEK L, HERCBERG S AND LATINO-MARTEL P. 2012. Excess body weight and second primary cancer risk after breast cancer: a systematic review and meta-analysis of prospective studies. Breast cancer research and treatment 135: 647-654.

EROLES P, BOSCH A, PÉREZ-FIDALGO JA AND LLUCH A. 2012. Molecular biology in breast cancer: intrinsic subtypes and signaling pathways. Cancer treatment reviews 38: 698-707.

HACHIM MY, HACHIM IY, DAI M, ALI S AND LEBRUN J-J. 2018. Differential expression of TGFβ isoforms in breast cancer highlights different roles during breast cancer progression. Tumor Biology 40: 1010428317748254.

HARRIS JR, LIPPMAN ME, VERONESI U AND WILLETT W. 1992. Breast cancer. New England Journal of Medicine 327: 319-328.

HORTOBAGYI GN, DE LA GARZA SALAZAR J, PRITCHARD K, AMADORI D, HAIDINGER R, HUDIS CA, KHALED H, LIU M-C, MARTIN M AND NAMER M. 2005. The global breast cancer burden: variations in epidemiology and survival. Clinical breast cancer 6: 391-401.

KAHR I, VANDEPOELE K AND VAN ROY F 2013. Delta-protocadherins in health and disease. Progress in molecular biology and translational science: Elsevier, p. 169-192.

MA G-F, MIAO Q, ZENG X-Q, LUO T-C, MA L-L, LIU Y-M, LIAN J-J, GAO H AND CHEN S-Y. 2013. Transforming growth factor-β1 and-β2 in gastric precancer and cancer and roles in tumor-cell interactions with peripheral blood mononuclear cells in vitro. PloS one 8: e54249.

NOOSHIN S, KARIZI SZ, KARIMIPOOR M AND NOOSHIN M. 2018. The Methylation Analysis of KLF11 and PCDH9 Genes in Patients with Non-Small Cell Lung Cancer. Cancer and Clinical Oncology 7: 47.

PEROU CM, SØRLIE T, EISEN MB, VAN DE RIJN M, JEFFREY SS, REES CA, POLLACK JR, ROSS DT, JOHNSEN H AND AKSLEN LA. 2000. Molecular portraits of human breast tumours. Nature 406: 747.

RAHIMI RA AND LEOF EB. 2007. TGF‐β signaling: A tale of two responses. Journal of cellular biochemistry 102: 593-608.

REDIES C, VANHALST K AND VAN ROY F. 2005. δ-Protocadherins: unique structures and functions. Cellular and Molecular Life Sciences CMLS 62: 2840-2852.

REIS-FILHO JS AND PUSZTAI L. 2011. Gene expression profiling in breast cancer: classification, prognostication, and prediction. The Lancet 378: 1812-1823.

WANG C, TAO B, LI S, LI B, WANG X, HU G, LI W, YU Y, LU Y AND LIU J. 2014. Characterizing the role of PCDH9 in the regulation of glioma cell apoptosis and invasion. Journal of Molecular Neuroscience 52: 250-260.

YOULDEN DR, BAADE PD, VALERY PC, WARD LJ, GREEN AC AND AITKEN JF. 2012. Childhood cancer mortality in Australia. Cancer epidemiology 36: 476-480.

YU J, KOUJAK S, NAGASE S, LI C, SU T, WANG X, KENIRY M, MEMEO L, ROJTMAN A AND MANSUKHANI M. 2008. PCDH8, the human homolog of PAPC, is a candidate tumor suppressor of breast cancer. Oncogene 27: 4657.


  • There are currently no refbacks.

Copyright (c) 2018 Arash Matin

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.